SCHEMBL4875175

SCHEMBL4875175

COc1ccc(-c2ccc3cc(-c4c(C5CCCCC5)c5sc(C(=O)O)cc5n4Cc4ccncc4)ccc3n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.38
FEN1 P39748 1/20 0.38
PDE5A O76074 1/20 0.37
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
CYP3A4 P08684 1/20 0.34
KCNH2 Q12809 1/20 0.34
BCHE P06276 1/20 0.34
ALOX5AP P20292 3/20 0.34
PPARG P37231 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
TSHR P16473 1/20 0.34
RAB9A P51151 1/20 0.34
ATM Q13315 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
WNT3A P56704 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4879012 0.91 ALOX5AP (0.35) PDE5AMAOAMAOBKCNH2ALOX5AP
SCHEMBL4872012 0.90 MDM2 (0.35) ALOX5AP
SCHEMBL4878276 0.89 MAOA (0.36) MAOAMAOBALOX5APPPARG
SCHEMBL4866901 0.88 GRIN1 (0.33) PDE5AKCNH2ALOX5AP
SCHEMBL4877200 0.87 KDM4E (0.33) KCNH2ALOX5APKDM4ETSHRSMN1; SMN2
SCHEMBL4868085 0.87 F10 (0.33) ALOX5APPPARGKDM4ESMN1; SMN2
SCHEMBL4871781 0.87 MAPT (0.37) FEN1ALOX5APPPARGHSD17B10
SCHEMBL4873267 0.86 ALOX5AP (0.34) ALOX5AP
SCHEMBL4872478 0.86 KCNH2 (0.39) KCNH2
SCHEMBL4878872 0.86 LMNA (0.37) CYP3A4ALOX5APKDM4ETSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
WO-2008008907-A2 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. (US) 2008-01-17 WO disclosed
WO-2008008912-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 ERCC5 2476/4885FEN1 226/4885PDE5A 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.